Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 2Head & Neck 2Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1ER+HER2- Breast Cancer 1Breast Neoplasms 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 485Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
18-O-demethylcervinomycin A2 × Breast × Clear all
NCT05445908 2026-05-08

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Active not recruiting
175 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07371208 2026-01-27

ST-A-TN

Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasms

NCT07109284 2025-08-07

NeoSaciA

West China Hospital

Phase 2 Not yet recruiting
55 enrolled
Breast

ER+HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡